Clinicopathological Diagnosis and Prognosis of Endometrioid Borderline Ovarian Tumors: Dual Case Reports and Literature Review
ABSTRACT
Introduction
Endometrioid borderline ovarian tumor (EBOT) is rare and frequently misdiagnosed. This study aims to investigate the clinicopathological features, immunohistochemical characteristics, differential diagnosis, therapeutic approaches and disease prognosis, thereby establishing a robust foundation to mitigate misdiagnosis risks and deepen insights into the pathological diagnosis of this disease.
Case Presentations
From May 2020 to December 2022, two female patients diagnosed with EBOT were enrolled at Ningbo Yinzhou No. 2 Hospital. The patients, aged 30 and 34 years, respectively, both underwent left adnexal resection. Microscopically, the tumors displayed disorganized crowded endometrioid glands, mild‐to‐moderate epithelial atypia, and fibrous stroma interspersed among glands. Mulberry‐like squamous metaplasia was also observed in some areas. Tumor cells were positive for cytokeratin (CK), cytokeratin 7 (CK7), estrogen receptor (ER) and progesterone receptor (PR), but negative for Wilms' tumor 1 (WT‐1). The Ki‐67 index ranged from 3% to 10%. Genetic analysis revealed a heterozygous
CTNNB1
deletion in one tumor, whereas a heterozygous
PTEN
deletion in the other. As of the current follow‐up (ranging from 10 to 40 months), both cases remained in a tumor‐free status, with no signs of recurrence or metastasis to date.
Conclusion
EBOT are infrequent and may coexist with endometriosis or endometrioid carcinoma. Our cases demonstrated a heterozygous deletion of the
CTNNB1
gene in one case, while a heterozygous deletion of the
PTEN
gene in the other. Surgery remains the main treatment, reflecting its efficacy in achieving disease control and a favorable prognosis.
